JS203

· Shanghai Junshi Bioscience Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for JS203, covering 2025-08-21 to 2025-12-02. Get the full timeline:

Most recent: Clinical Trial Update: Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma [Phase 1]